Latest News

Servier and MiNA Therapeutics sign €220m deal

Moa of saRNAs. Small activating RNAs (saRNAs) are double-stranded RNA molecules (dsRNAs) that are precisely matched to gene promoters. The transcription of targeted genes is activated and the proteins that are missing depending on the indication are produced. © MINA Therapeutics


by tg

French Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.

Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell function in neurological disorders. Servier will be responsible for preclinical and clinical development of lead candidates and will have the rights for the commercialisation of any products resulting from the collaboration. Under the terms of the agreement, MiNA Therapeutics can receive up to €220m including an upfront payment, an exclusivity fee on selected neurological targets and milestone payments as well as royalties.

saRNAs activate gene expression thus unlocking potential for the treatment of neurodegenerative diseases with limited treatment options, particularly in the neurology and immuno-inflammation area. The collaboration is an extension to MiNA Therapeutics’ R&D activities that has been so far focussed on liver cancer.

J&J starts European COVID-19 vaccine roll-out

According to the EMA, the very rare cases of cerebral venous thrombosis, which were observerd after vaccination with J&J’s COVID-19 jab, didn't...

Targeting SARS-CoV-2 differently

Using X-ray crystallography, Sebastian Günther and colleagues screened more than 5,000 drug compounds, identified seven compounds that bind to Mpro,...

EU orders 100 million additional doses from Biontech

To avoid supply shortages that could occur as a result of restricted use of adenoviral COVID-19 vaccines, the European Commission has acquired...

German antibodies in demand in USA

Initially, Seattle-based Just - Evotec Biologics will receive US$28.6m from the Defense Health Agency ("DHA") under a partnership announced...

MaxiVAX and Minaris Regenerative Medicine ink contract

Under the contract, Minaris will be responsible for the GMP manufacturing, freezing and shipping of MVX-ONCO-2, a cell-based immunotherapy for the...

EMA starts rolling review for Sputnik V vaccine

The EU applicant for Gam-COVID-Vac is R-Pharm Germany GmbH. The CHMP’s decision to start the rolling review is based on results from laboratory...

Janssen to pledge COVID-19 vaccine to African Union

The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500 million doses of JNJ’ adenoviral...